Navigation Links
Visikol Launches New Website to Better Highlight its Contract Research Services
Date:2/26/2019

The idea for Visikol began originally at Rutgers University in 2012 when Visikol Co-Founder Dr. Thomas Villani developed the Visikol® tissue clearing technology for improved tissue characterization. From this initial idea, Visikol emerged as a company and has since transitioned from a products focused company to primarily a services focused company.

Today, Visikol operates as a contract research organization with a distinct expertise in 3D cell culture assays, 3D cell culture models, 3D tissue imaging, digital pathology and custom drug discovery projects. The focus of the company is to help pharmaceutical companies accelerate their drug discovery and development efforts through the quantitative analysis of tissues and leveraging advanced in vitro systems. “Our Clients see us as a leader in imaging, image analysis and advanced in vitro biology. With our agnostic approach to diseases, tissues and models, we work on a very wide range of projects from high content screening to end-to-end animal studies,” described Visikol Chief Science Officer Dr. Tom Villani.

The launch of the new Visikol website is designed to better showcase its unique service offering and capabilities which span from simple slide scanning and plate reading to large scale screening assays, 21 CFR part 11 compliant machine learning applications and customized organoid models. “When many people think of Visikol they think of our tissue clearing reagents and kits which have been used by over 500 research labs from around the world. However, while we still sell these reagents and use them in some of our Client projects, the focus of our company is now primarily on our services and providing pharmaceutical companies with best-in-class services. Over the last year we have greatly expanded our service offering and want to better showcase these assays and capabilities to our potential Clients,” explained Visikol Chief Executive Officer Dr. Michael Johnson.

In 2019 Visikol will continue to build out its service offering and will continue to push the envelope on transforming tissues into actionable insights for its Clients.

About Visikol
Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

Read the full story at https://www.prweb.com/releases/visikol_launches_new_website_to_better_highlight_its_contract_research_services/prweb16124495.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Visikol to Present Three Talks at SLAS Highlighting 3D Cell Culture Assay Services
2. Visikol CEO Dr. Michael Johnson Named to 2019 Forbes 30 Under 30 List as a Top Three All Star Alumni
3. Visikol Machine Learning Digital Pathology Services for Drug Discovery
4. Dr. Michael Johnson, CEO and Co-founder of Visikol, Invited to Speak with Governor Murphy on Behalf of the Science, Innovation, and Technology Commission Bill
5. VetStem Biopharma Launches Human Stem Cell Company in San Diego
6. New Equipment Alert: Boekel Scientific launches Its New Touch Screen Blood Collection Mixer
7. Calidi Biotherapeutics Launches Scientific and Medical Advisory Board
8. USDM Life Sciences Launches Redesigned Website
9. ISBER Launches Chinese Translation of Best Practices: Recommendations for Repositories, Fourth Edition
10. World’s First Self-Learning Snore Mask Launches on Indiegogo
11. National Laboratory Launches Partnership with Frederick CREST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2019)... ... May 14, 2019 , ... Gateway Genomics , a leading developer ... from 2,500 to 5,000 square feet. , “This past year has seen exponential ... Gateway Genomics CEO, Chris Jacob. “The SneakPeek At-Home test, which is mailed directly to ...
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys Inc, the world leader ... Response vision test, a new full field electroretinography (ffERG) protocol designed to ... million Americans will have glaucoma, with black Americans having the highest prevalence rate. ...
(Date:5/2/2019)... ... May 02, 2019 , ... Researchers from Ambry ... discrepancies between U.S. insurer policies for genetic testing and the 2019 National Comprehensive ... and ovarian cancer (HBOC). , Jill S. Dolinsky, director of clinical ...
(Date:4/18/2019)... WORCESTER, Mass. (PRWEB) , ... April 18, 2019 ... ... for fossil fuels, a research team that includes a chemical engineer at Worcester ... an exotic microorganism that may make it possible to manufacture isobutanol and other ...
Breaking Biology Technology:
(Date:5/21/2019)... (PRWEB) , ... May 21, 2019 , ... ... the environment, how will we know? How can we tell it apart from ... being taken on by a multi-institution research team, including Eric Young , ...
(Date:5/21/2019)... ... 20, 2019 , ... Dr. David Greene , Founder and CEO of ... Therapy: Biotechnology to the Rescue, was produced by Award Winning filmmaker Dr. Elliott Haimoff. ... regards to the safety of the procedures along with the potential for helping patients ...
(Date:5/16/2019)... ... May 16, 2019 , ... In a FDA-contracted Standard Coordinating ... Maryland, March 18-19 of this year, Asymmetrex founder and director James L. ... for counting therapeutic adult tissue stem cells. Many of the gathered participants dismissed ...
Breaking Biology News(10 mins):